Our half year results to 30 June 2026 show a business that's converting growth into cash. Revenue rose 6.3% to £20.4m, EBITDA grew 27.1% to £2.6m, and free cash flow more than doubled to £1.5m. Cash on hand grew 60.3% to £7.7m.

We used part of that cash to fund our £0.9m acquisition of a weight management business, completed on 8 May 2026, without raising new capital. The acquisition, now trading as DCA Medicspot, gives us an immediate position in GLP-1 weight-loss treatment and contributed £0.9m of revenue in the period, operating at approximately breakeven.

We're also broadening our revenue base beyond our historic insurer channel. Non insurance revenue grew to 11% of total revenue, up from 7% a year earlier. We've included an illustrative pro forma showing that if DCA Medicspot's current monthly revenue continued at its present rate, non insurance revenue would represent around 19% of the total. This is not a forecast, just a way of showing the direction of travel.

Patient engagement remains strong, with three quarters of consultations now delivered to people who've used us before. Our new partnership with Ramsay Health Care UK connects our GP service into a wider hospital and specialist network.

Net profit for the half was £0.6m, up 28.5%. In July, ASX granted us relief from quarterly reporting requirements in recognition of our sustained cash generation.

If you have questions about these results, we'd encourage you to ask them through our investor hub.